Interim results of a randomized trial with 11,266 adults in 405 hospitals in 30 countries. Conclusions: "These Remdesivir, Hydroxychloroquine, Lopinavir and In

Interim results of a randomized trial with 11,266 adults in 405 hospitals in 30 countries. Conclusions: "These Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay. The mortality findings contain most of the randomized evidence on Remdesivir and Interferon, and are consistent with meta-analyses of mortality in all major trials."